Mustang Bio, Inc. (MBIO) soared last Thursday after the very successful results of its gene therapy, MB-107, for X-linked Severe Combined Immunodeficiency, or X-SCID, were published in the New England Journal of Medicine. The therapy, licensed from the St. Jude Children's Research Hospital, has been shown to be safe and effective in eight patients with X-SCID, better known as "Bubble Boy" disease. This news attained mainstream coverage with both the BBC and CNN reporting on it, which was a major driving force behind the stock price increasing.
As a 38% shareholder of MBIO,